CORT Stock Cash Flow Statements

Corcept Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Corcept Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-05-13	2011-05-13	2010-05-13	2010-03-31	2009-06-30	2009-05-13	2008-12-31	2008-09-30	2008-05-13	2008-03-31	2007-03-31	2006-12-31	2006-09-30	2004-12-31	2004-09-30	2004-05-13	2004-03-31

cash flows from operating activities:
net income	35,149,000	20,547,000	30,746,000	47,213,000	35,488,000	27,762,000	31,355,000	31,378,000	27,528,000	15,879,000	16,601,000	34,608,000	27,412,000	22,797,000	32,053,000	30,471,000	26,523,000	23,465,000	25,994,000	21,625,000	28,327,000	30,065,000	29,381,000	26,340,000	20,186,000	18,274,000	22,008,000	17,747,000	18,196,000	17,459,000	98,330,000	13,757,000	4,597,000	2,585,000	977,000	-19,000	959,000	-601,000	-1,936,000	-4,830,000	-3,895,000	-6,007,000	-7,551,000	-13,930,000	-11,124,000	-10,906,000	-11,897,000	-12,084,000	-11,124,000	-8,294,000	-7,596,000	-11,034,000	-183,305,000	-5,695,000	-156,311,000	-4,878,000	-135,522,000	-6,171,000	-5,565,000	-4,395,000	-113,941,000	-100,973,000	-3,877,000	-6,402,000	32,626,380	-4,088,765	-3,583,741	-40,488,355
adjustments to reconcile net income to net cash from operations:
stock-based compensation	19,023,000	21,830,000	16,796,000	16,102,000	15,207,000	13,249,000	13,065,000	12,876,000	11,858,000	11,141,000	10,521,000	10,554,000	10,606,000	10,761,000	10,810,000	10,952,000	11,068,000	10,101,000	8,430,000	8,702,000	8,489,000	7,918,000	7,610,000	7,271,000	7,736,000	6,696,000	6,266,000	6,510,000	6,017,000	4,954,000	3,832,000	3,623,000	1,957,000	1,831,000	1,657,000	1,613,000	1,493,000	1,543,000	1,568,000	1,409,000	1,387,000	1,211,000	1,225,000	1,378,000	1,313,000	1,308,000	1,265,000	1,310,000
accretion of marketable securities	-1,312,000	-1,693,000
depreciation and amortization	286,000	285,000	281,000	318,000
deferred income taxes	-17,764,000	-13,705,000	-3,858,000	-15,207,000	-13,964,000	-7,162,000	-3,672,000	-8,857,000	-10,238,000	-6,726,000	-4,467,000	-8,873,000	-10,630,000	-9,935,000	2,299,000	4,108,000	3,299,000	-5,360,000	2,311,000	1,761,000	4,922,000	5,095,000	5,146,000	5,897,000	4,908,000	926,000	3,465,000	4,960,000	2,473,000	3,169,000
non-cash amortization of right-of-use asset	183,000	177,000				59,000	58,000	57,000	637,000	568,000	564,000	557,000	552,000	514,000	508,000	502,000	496,000	489,000	484,000	479,000	385,000	364,000
changes in operating assets and liabilities:
trade receivables	-2,748,000	-7,843,000	5,741,000	-5,880,000	7,681,000	-20,395,000	-6,497,000	-2,073,000	4,000	-1,500,000	-1,643,000	-1,250,000	-986,000	447,000	-1,117,000	1,112,000	-5,420,000	3,998,000	-4,241,000	768,000	3,959,000	-6,756,000	2,477,000	-2,631,000	-556,000	-1,630,000	1,772,000	9,344,000	-11,443,000	-1,961,000	-3,428,000	-2,368,000	-1,624,000	1,065,000	-2,549,000	-531,000	-276,000	-994,000	-650,000	-967,000	-588,000	-521,000	-303,000	-494,000	-409,000	-164,000	288,000	-586,000	-203,000	1,000
insurance recovery receivable related to melucci litigation			0	0	0	14,000,000
inventory	-4,626,000	605,000	-78,000	1,081,000	-1,681,000	983,000	329,000	-544,000	922,000	558,000	125,000	419,000	818,000	-163,000	789,000	797,000	992,000	866,000	-4,208,000	-720,000	86,000	1,328,000	-390,000	889,000	-2,453,000	910,000	-3,433,000	-2,275,000	-2,661,000	590,000	-1,918,000	791,000	143,000	-1,213,000	98,000	290,000	112,000	277,000	169,000	257,000	211,000	132,000	-183,000	89,000	9,000	-11,000	-868,000	-13,000	-2,186,000	-40,000	-2,381,000	-56,000
prepaid expenses and other current assets	11,293,000	-13,525,000	-3,040,000	6,594,000	-1,744,000	3,612,000					4,285,000	-5,322,000	-5,034,000	-9,000	-1,309,000	-241,000			1,229,000	-2,603,000	370,000	351,000	1,754,000	-1,596,000	-461,000	1,999,000	-3,465,000	-696,000	-275,000	-635,000	417,000	-559,000	-643,000	105,000	-320,000	-464,000	538,000	61,000	-619,000	819,000	328,000	397,000	-713,000	-543,000	94,000	-203,000	-229,000	48,000	180,000	-192,000	-506,000	38,000	-604,000	-40,000	-581,000	-646,000	-328,000	420,000	-52,000	-1,077,000	-561,000	-368,000	157,000	98,000		205,830	-530,749	-347,940
other assets			363,000	-34,000	-551,000	153,000					23,000	-3,247,000			1,023,000	34,000			10,000	-474,000	-1,095,000	7,000	-3,298,000	0	-75,000	-25,000		0	20,000	-23,000	12,939,000	-12,940,000								-10,000	1,000	-3,000	3,000	9,000		0	0	-3,000	8,000	231,000	-188,000	-40,000	-28,000	-6,000	-80,000	6,000	-180,000	-6,000	-106,000	-1,000	-63,000	-61,000	5,000	-3,000		-4,644	-178	-51,678
accounts payable	-4,780,000	12,929,000	-3,864,000	-113,000	6,590,000	-4,861,000	995,000	8,585,000	-3,153,000	-649,000	4,242,000	-165,000	-1,576,000	2,256,000	364,000	-2,657,000	2,189,000	-3,493,000	4,149,000	263,000	1,349,000	-2,600,000	1,689,000	-1,125,000	-2,252,000	953,000	-5,732,000	7,557,000	-1,455,000	-759,000	2,367,000	4,138,000	-2,019,000	2,228,000	-1,000	757,000	-415,000	-620,000	1,324,000	-850,000	-74,000	-635,000	-1,071,000	1,285,000	44,000	-696,000	770,000	-1,541,000	2,230,000	-2,661,000	2,151,000	-1,527,000	1,865,000	150,000	1,023,000	-901,000	1,571,000	301,000	-95,000	220,000	878,000	809,000	-1,702,000	1,353,000		350,714	136,742	493,023
accrued research and development expenses	3,789,000	-8,608,000	6,132,000	5,764,000	-2,852,000	3,494,000	25,000	2,698,000	4,626,000	-592,000	802,000	-32,000	752,000	609,000
accrued and other liabilities	5,945,000	-5,939,000	10,711,000	19,624,000	-1,207,000	9,114,000	-19,046,000	17,416,000	11,252,000	8,027,000	1,180,000	4,668,000	-7,916,000	4,995,000	3,341,000	2,805,000	3,550,000	-3,217,000	2,232,000	-3,687,000	3,048,000	-3,676,000	1,690,000	5,142,000
accrued settlement related to melucci litigation			0	0	0	-14,000,000
long-term accrued income taxes	1,424,000	169,000	1,237,000	910,000	1,068,000	562,000	-163,000	518,000	553,000	302,000	2,274,000	1,842,000	2,465,000	2,107,000				597,000
operating lease liability	-230,000	-101,000	145,000	142,000	-29,000	-75,000	-74,000	-72,000	-575,000	-568,000	-564,000	-557,000	-552,000	-526,000	-520,000	-513,000	-508,000	-484,000					-344,000	-378,000	-373,000	-357,000
net cash from operating activities	43,939,000	5,128,000	59,300,000	73,829,000	41,182,000	23,756,000	5,887,000	52,909,000	42,286,000	25,957,000	33,388,000	33,648,000	18,040,000	35,247,000	49,427,000	48,704,000	44,339,000	25,422,000	35,071,000	30,444,000	53,186,000	33,269,000	48,454,000	38,427,000	25,555,000	23,681,000	21,519,000	44,505,000	15,211,000	34,430,000	24,883,000	10,925,000	4,569,000	8,935,000	1,590,000	3,297,000	4,163,000	883,000	-139,000	-1,777,000	-1,403,000	-5,929,000	-8,984,000	-11,060,000	-7,666,000	-8,602,000	-9,236,000	-11,554,000	-8,742,000	-9,229,000	-7,892,000	-10,157,000	-161,464,000	-4,517,000	-137,771,000	-6,195,000	-117,580,000	-4,494,000	-3,952,000	-5,448,000	-100,022,000	-88,211,000	-5,543,000	-5,460,000	25,498,489	-3,439,828	-3,151,331	-32,625,253
capex	-57,000	-104,000	-121,000	-1,635,000	0	0	0	-37,000	0	0	-31,000	-351,000	-19,000	-12,000	-65,000	-159,000	-119,000	-126,000	-431,000	-718,000	-47,000	-42,000	-135,000	-286,000	-410,000	-257,000	-113,000	-45,000	-63,000	-77,000	-29,000	-82,000	-75,000	-90,000	-7,000	-22,000	17,000	0	0	-34,000	0	-16,000	-48,000	-110,000	-40,000	-65,000	-4,000	-18,000	-58,000	-52,000	-34,000	-7,000	-61,000	0	-61,000	0	-61,000	-7,000	0	0	-54,000	-54,000	0	0	0	0	0	-53,966
free cash flows	43,882,000	5,024,000	59,179,000	72,194,000	41,182,000	23,756,000	5,887,000	52,872,000	42,286,000	25,957,000	33,357,000	33,297,000	18,021,000	35,235,000	49,362,000	48,545,000	44,220,000	25,296,000	34,640,000	29,726,000	53,139,000	33,227,000	48,319,000	38,141,000	25,145,000	23,424,000	21,406,000	44,460,000	15,148,000	34,353,000	24,854,000	10,843,000	4,494,000	8,845,000	1,583,000	3,275,000	4,180,000	883,000	-139,000	-1,811,000	-1,403,000	-5,945,000	-9,032,000	-11,170,000	-7,706,000	-8,667,000	-9,240,000	-11,572,000	-8,800,000	-9,281,000	-7,926,000	-10,164,000	-161,525,000	-4,517,000	-137,832,000	-6,195,000	-117,641,000	-4,501,000	-3,952,000	-5,448,000	-100,076,000	-88,265,000	-5,543,000	-5,460,000	25,498,489	-3,439,828	-3,151,331	-32,679,219
cash flows from investing activities:
purchases of property and equipment	-57,000	-104,000	-121,000	-1,635,000			0	-37,000			-31,000	-351,000	-19,000	-12,000	-65,000	-159,000	-119,000	-126,000	-431,000	-718,000	-47,000	-42,000	-135,000	-286,000	-410,000	-257,000	-113,000	-45,000	-63,000	-77,000	-29,000	-82,000	-75,000	-90,000	-7,000	-22,000	17,000	0	0	-34,000	0	-16,000	-48,000	-110,000	-40,000	-65,000	-4,000	-18,000	-58,000	-52,000	-34,000	-7,000	-61,000	0	-61,000	0	-61,000	-7,000	0	0	-54,000	-54,000	0	0		0	0	-53,966
proceeds from sales and maturities of marketable securities	93,458,000	112,078,000
purchases of marketable securities	-23,274,000	-115,145,000	-144,572,000	-223,134,000	-142,728,000	-77,876,000	-29,902,000	-210,031,000			-96,644,000	-78,851,000	-86,960,000	-92,611,000	0	-89,537,000	-95,880,000	-127,388,000	-97,020,000	-103,780,000	-170,845,000	-48,469,000	-75,704,000	-92,330,000	-60,066,000	-70,935,000	-55,799,000	-81,661,000	-44,798,000	-50,866,000	-27,419,000	-11,565,000
net cash from investing activities	70,127,000	-3,171,000	-64,360,000	-44,036,000	-60,194,000	-9,014,000		-109,570,000	-24,097,000	207,475,000	-17,241,000	-4,790,000	-41,800,000	-50,496,000	140,471,000	-25,803,000	24,742,000	-3,284,000	11,220,000	-64,273,000	-85,944,000	19,734,000	-61,989,000	-54,316,000																									-58,000	-52,000	-34,000	-7,000	-61,000	0	-61,000	1,450,000	-1,511,000	2,931,000	-6,532,000	0	-54,000	-54,000	8,196,000	4,939,000	-9,695,616	-9,771,752	-19,992,116	-53,966
cash flows from financing activities:
proceeds from stock option exercises, net of issuance costs	9,235,000	1,740,000	889,000
proceeds from purchases under the employee stock purchase program	3,275,000	1,715,000	1,532,000	1,289,000	1,698,000	940,000
repurchases of common stock in connection with stock repurchase program	-103,018,000	-27,433,000
cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants	-12,426,000	-15,825,000	-6,985,000	-11,651,000	-1,909,000	-1,756,000	-995,000	-5,059,000	-1,824,000	-1,228,000	-846,000
net cash from financing activities	-102,934,000	-39,803,000	-4,564,000	-21,092,000	-2,150,000	-543,000	766,000	-3,916,000	-145,754,000	181,000	-61,000	-13,961,000	-2,756,000	-506,000	-206,969,000	-23,643,000	-26,032,000	-45,947,000	-661,000	5,866,000	6,804,000	205,000	-144,000	2,696,000	-15,908,000	-15,289,000	-12,031,000	-8,270,000	4,044,000	1,922,000	2,567,000	-1,841,000	-823,000	-2,769,000	-538,000	-2,966,000	-195,000	-1,481,000			-1,129,000	-1,249,000	-612,000	-89,000	-592,000				204,000	76,010,000	198,000	13,156,000	220,726,000	21,354,000	156,380,000	-2,000	138,285,000	-41,000	681,000	-220,000	131,867,000	103,009,000	2,957,000	-2,000	-41,969,421	0	49,385,252	41,672,556
net effect of exchange rate changes on cash and cash equivalents
net decrease in cash and cash equivalents														-15,755,000																												-7,194,000	-9,644,000	-11,259,000
cash and cash equivalents, at beginning of period	0	127,665,000	0	0	0	135,551,000	0	0	0	66,329,000	0	0	0	77,617,000	0	0	0	76,190,000	0	0	0	31,269,000	0	0	0	41,625,000	0	0	0	31,062,000	0	0	0	0	0	40,435,000		0	0	24,248,000		0	0	54,877,000		0	0	93,032,000		0	0	39,635,000
cash and cash equivalents, at end of period	12,926,000	89,819,000	-9,624,000	8,701,000	-21,162,000	149,750,000	23,751,000	-60,577,000	-127,565,000	299,942,000	16,086,000	14,897,000	-26,516,000	61,862,000	-17,071,000	-742,000	43,049,000	52,381,000	45,630,000	-27,963,000	-25,954,000	84,477,000	-13,679,000	-13,193,000	8,491,000	49,650,000	7,731,000	2,729,000	-1,956,000	33,121,000	2,000	-2,563,000	3,671,000	6,076,000	1,045,000	40,744,000		-598,000	-905,000	37,953,000		-7,194,000	-9,644,000	43,618,000		-9,045,000	-9,240,000	81,460,000		66,729,000	-7,728,000	42,627,000	59,201,000	16,837,000	18,548,000	-4,747,000	19,194,000		-9,803,000	-5,668,000	31,791,000	14,744,000		-523,000
net increase in cash and cash equivalents		-37,846,000	-9,624,000	8,701,000	-21,162,000	14,199,000	23,751,000	-60,577,000	-127,565,000	233,613,000	16,086,000	14,897,000			-17,071,000	-742,000	43,049,000	-23,809,000	45,630,000	-27,963,000	-25,954,000	53,208,000	-13,679,000	-13,193,000	8,491,000	8,025,000	7,731,000	2,729,000	-1,956,000	2,059,000	2,000	-2,563,000	3,671,000	6,076,000	1,045,000	309,000	3,985,000	-598,000	-905,000	13,705,000					-8,298,000	-9,045,000	-9,240,000	-11,572,000	-8,596,000	66,729,000	-7,728,000	2,992,000	59,201,000	16,837,000	18,548,000	-4,747,000	19,194,000	-1,604,000	-9,803,000	-5,668,000	31,791,000	14,744,000	5,610,000	-523,000	-26,166,548	-13,211,580	26,241,805	8,993,337
supplemental disclosure:
exercise cost of shares repurchased for net settlement of cashless option exercises		5,261,000				1,798,000		13,667,000	3,286,000	5,246,000	2,413,000
adjustments to reconcile net income to net cash from operating activities:
(accretion) of discount and amortization of premium on marketable securities
amortization of right-of-use asset			179,000	181,000																			332,000	364,000	359,000	413,000
proceeds from maturities of marketable securities			80,333,000	180,733,000	82,950,000	68,862,000	47,000,000	100,498,000	64,820,000	207,475,000	79,434,000	74,412,000	45,179,000	42,127,000	90,073,000	63,893,000	120,741,000	124,230,000	108,671,000	40,225,000	84,948,000	68,245,000	13,850,000	38,300,000	59,320,000	70,825,000	54,155,000	48,200,000	23,650,000	16,650,000
repurchase of common stock in connection with tender offer							0	0
income taxes paid
accretion of discount on marketable securities				-2,866,000
repurchase of common stock in connection with stock repurchase program				-11,710,000	-3,478,000	-476,000
proceeds from issuance of common stock under our incentive award plan, net of issuance costs					1,539,000	749,000	1,761,000	1,143,000	1,498,000	1,409,000	785,000
(accretion) of discount on marketable securities						-2,859,000
amortization of cloud computing arrangements						52,000
depreciation and amortization of property and equipment						68,000	107,000	112,000	186,000	172,000	183,000	195,000	116,000	288,000	289,000	269,000	260,000	254,000	78,000	85,000	124,000	238,000	229,000	211,000	167,000	96,000	73,000	58,000	57,000	48,000	48,000	36,000	15,000	21,000	24,000	27,000	28,000	30,000	57,000	40,000	37,000	39,000	37,000	28,000	21,000	20,000	19,000	14,000			5,000	3,000	116,000	2,000	113,000	2,000	103,000	2,000	3,000	4,000	91,000	78,000	4,000	3,000
other
proceeds from sales of marketable securities
net cash provided (used in) by investing activities
amortization of interest income								-2,753,000	-1,677,000	-1,503,000	-738,000	251,000	764,000	1,106,000
prepaid expenses and other assets								-6,432,000	363,000	848,000								-2,850,000
recognition of right-of-use asset and lease liability								0			0	0	0	2,816,000					0	0			3,035,000	0	0	1,878,000
excise tax payable
repurchase of common stock																-25,774,000	-29,170,000	-33,541,000	-9,670,000	0	0	-275,000	0	0	-17,420,000	-13,555,000	-14,753,000
proceeds from exercise of stock options, net of issuance costs													550,000	1,382,000	3,047,000	4,396,000	4,748,000	4,038,000
cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises													-3,306,000	-1,888,000		-2,265,000	-1,610,000	-16,444,000
cost of shares repurchased for net settlement of cashless option exercises													6,060,000	5,149,000		2,001,000	1,659,000	6,045,000
amortization (accretion) of interest income																	1,277,000	1,194,000	899,000
others																			0	0
accrued clinical expenses															-402,000	-269,000	-453,000	-138,000	-1,828,000	4,243,000	3,351,000	1,461,000	2,356,000	-1,597,000	1,181,000	1,016,000	-1,871,000	-5,000	1,911,000	1,239,000	355,000	381,000	-308,000	812,000	-131,000	-77,000	562,000	117,000	-866,000	1,022,000	60,000	-1,367,000	-1,737,000	92,000	1,325,000	919,000	461,000	-260,000	238,000	-35,000	-141,000	137,000	694,000											-1,009,000
cash paid to satisfy statutory withholding requirement for the net settlement of cashless option exercises
cost of shares repurchased for net settlement of cashless option exercise
other receivable																											0	0	20,000	12,876,000
cash paid to satisfy statutory withholding requirement for the net settlement of cashless option exercise
adjustments to reconcile net income to net cash generated from operations:
operating lease liabilities																				-474,000	-382,000	-349,000
proceeds from issuance of common stock upon exercise of options, net of issuance costs																				5,893,000	6,867,000	480,000		2,696,000	1,512,000	2,435,000		634,000	4,044,000	1,922,000
cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercise																				-27,000				0	0	-4,169,000
exercise price of shares tendered in net settlement of cashless option exercise																				128,000				0	0	931,000
accretion of interest income																					105,000	-177,000	-325,000	-360,000	-419,000	-634,000	-701,000	-474,000	-348,000	-198,000
amortization of debt financing costs																															0	3,000	5,000	5,000	6,000	5,000	2,000	9,000	5,000	6,000	6,000	9,000	6,000	8,000	8,000	8,000	8,000	11,000
excess tax benefits from stock option activity																														54,000
payments related to debt obligation
other accrued liabilities																										-4,956,000	2,895,000	1,779,000	2,753,000	-2,383,000	1,247,000	4,026,000	2,079,000	1,041,000	1,306,000	1,270,000	425,000	325,000	88,000	543,000	337,000	-85,000	353,000	-30,000
cash from investing activities																										-367,000		-33,506,000	-21,211,000	-34,293,000	-27,448,000	-11,647,000	-75,000	-90,000	-7,000	-22,000	17,000	0	0	-34,000	0	-16,000	-48,000	-110,000	-40,000	-65,000	-4,000	-18,000
deferred revenue																																	0	0	0	-158,000	79,000	42,000	-18,000	22,000	-17,000	6,000	15,000	4,000	-30,000	18,000	-39,000	60,000	-5,000	-5,000
accretion of interest expense																															0	37,000	367,000	455,000	523,000	584,000	652,000	697,000	737,000	762,000	804,000	895,000	935,000	1,044,000	1,070,000	1,133,000	1,092,000	1,115,000	1,105,000
deferred taxes
proceeds from exercise of warrants, net of issuance costs
proceeds from issuance of common stock upon exercise of options and warrants, net of issuance costs																																2,772,000		1,267,000	2,731,000	75,000		1,009,000	1,322,000	17,381,000
payments related to long-term obligation																																-4,613,000	-4,433,000	-4,036,000	-3,269,000	-3,041,000	-2,764,000	-2,490,000	-2,088,000	-1,865,000	-1,568,000	-1,276,000	-1,017,000	-995,000
adjustments to reconcile net income to net cash generated from (used in) operations:
operating activities
investing activities
financing activities
cash and cash equivalents at beginning of period
cash and cash equivalents at end of period																																																																	-16,093,445	-13,211,580	26,241,805	8,993,337
net cash provided (used) in financing activities																																								15,516,000
proceeds from issuance of common stock and warrants, net of issuance costs																																											405,000	906,000
proceeds from issuance of long-term obligation, net of issuance costs
accrued compensation and other liabilities																																													14,000	-28,000	-106,000	375,000
proceeds from issuance of common stock and warrants, including collection of stockholder notes receivable, net of cash paid for issuance costs
proceeds from issuance of long-term obligation, net of cash paid for issuance costs
payment related to long-term obligation
principal payments of obligations under capital leases																																																					-59,000	-4,000	-55,000	-2,000	-45,000	-3,000	-4,000	-3,000	-33,000	-20,000	-3,000	-3,000
non-cash expense related to stock options
other liabilities																																																		183,000	210,000	-66,000	637,000	139,000	424,000	102,000	377,000	-933,000	1,098,000	-141,000	535,000	454,000	-104,000	123,000
proceeds from issuance of common stock and warrants, including collection of notes receivable, net of issuance costs																																																		46,150,000	198,000	13,156,000	178,864,000	21,358,000	114,514,000	0	96,409,000
expense related to stock options
expense related to stock options, net of recoveries																																																				2,388,000
expense related to stock issued for services or in conjunction with license agreement																																																					95,000	0	95,000	0	79,000		0	4,000	75,000	75,000		0
expense related to stock issued below fair value																																																					522,000	0	522,000	0	522,000	0	0	0	522,000	522,000	0	0		17,000	17,000	380,487
interest accrued on convertible promissory note																																																					104,000	0	104,000	0	104,000		0	0	104,000	104,000		0
settlement of liquidated damages in stock																																																					1,281,000	0	1,281,000	0	1,281,000
purchases of investments																																																					-118,320,000
maturities of investments																																																					118,320,000
proceeds from issuance of convertible preferred stock, net of cash paid for issuance costs																																																					40,378,000	0	40,378,000	0	40,378,000	0	0	0	40,378,000	40,378,000	0	0		0	0	40,378,669
proceeds from issuance of convertible notes																																																					1,543,000	0	1,543,000	0	1,543,000		0	0	1,543,000	1,543,000		0
expense related to stock options, net of reversals																																																					17,159,000	502,000	14,947,000	467,000	13,088,000		398,000	408,000	11,454,000	10,230,000		377,000
stock-based compensation, net of recoveries
expense related to stock issued for services																																																																		0	0	45,696
expense related to stock issued in conjunction with license agreement																																																																		0	0	14,570
interest accrued on convertible promissory notes																																																																		0	5,208	98,561
purchases of short-term and long-term investments																																																							-118,320,000	6,000	-118,326,000	2,938,000	-6,532,000	0	-114,726,000	-108,346,000	-4,000	-1,000
maturities of short-term investments																																																							118,320,000	1,444,000	116,876,000										0	14,809,823
supplemental disclosure of cash flow information
interest paid
supplemental disclosure of non-cash financing activities
conversion of convertible promissory notes and accrued interest
—to convertible preferred stock
—to common stock
issuance of warrant in connection with financing agreement
issuance of common stock in settlement of liquidated damages
purchase of equipment under capital leases
accrued clinical expense
accrued clinical																																																							692,000	-347,000	1,325,000	208,000	367,000	-470,000	884,000	919,000
proceeds from issuance of common stock and warrants, including collection of note receivable, net of cash paid for issuance costs
proceeds from issuance of common stock, net of cash paid for issuance costs																																																														60,935,000	2,917,000	1,000	-73,190	0
proceeds from issuance of convertible note payable																																																																		0	0	462,929
proceeds from convertible promissory notes
proceeds from repayment of stockholder notes																																																										0	0	6,000	177,000	173,000	43,000	0
issuance of note receivable pursuant to sale of common stock and warrant
sales and maturities of short-term investments																																																											0	0	114,726,000
proceeds from issuance of common stock and warrants, net of note receivable and cash paid for issuance costs																																																											685,000	-223,000	89,802,000
- to convertible preferred stock																																																											0	0	1,111,000
- to common stock																																																											0	0	534,000
issuance of note receivable for sale of common stock and warrants																																																											0	0	6,000,000
maturities of short-term and long-term investments																																																														108,346,000		4,940,000
depreciation																																																																		0	0	53,966
amortization of deferred compensation, net of reversals																																																																		197,322	540,132	6,662,569
accrued liabilities																																																																		-117,285	264,255	513,848
proceeds from issuance of convertible notes payable
proceeds from issuance of capital leases, net of short-term portion
proceeds from repayment of stockholder note																																																																	25,117	0	0	37,300
purchases of short-term investments																																																																			-19,992,116	-14,809,823
payment to repurchase common stock																																																																		0	0	-250
supplemental disclosure of noncash financing activities:
issuance of preferred stock for services
supplemental disclosure of cash flow information:
proceeds from issuance of convertible promissory notes																																																																		0	0	1,080,000
supplemental disclosure of non-cash financing activities:
to common stock
to convertible preferred stock
payment of issuance costs related to initial public offering																																																																				-360,000
proceeds from issuance of common stock																																																																				73,908

We provide you with 20 years of cash flow statements for Corcept Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Corcept Therapeutics stock. Explore the full financial landscape of Corcept Therapeutics stock with our expertly curated income statements.

The information provided in this report about Corcept Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.